ArticleEJHaem2022
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
Naveen Pemmaraju et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this papercites it
ArticleEJHaem2022
Naveen Pemmaraju et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.